Change the brand Change the cost Join the change to carbon neutral All by choosing Bibecfo - the new beclometasone/formoterol combination from Cipla 1-6
Bibecfo is a low-cost, carbon offset combination of beclometasone (100mcg or 200mcg) and formoterol (6mcg)1-4
Bibecfo 100/6mcg and 200/6mcg strengths offer patients the same active ingredients in the same inhaler type as Fostair (beclometasone/formoterol), at a lower cost. Bibecfo is also a lower price than Luforbec (beclometasone/formoterol). A list price of just £13.98 could deliver savings. 1-3,5,6,10,11
From the launch of Bibecfo, Cipla is committed to making use of carbon offsetting to minimise its environmental footprint.4
Cipla is committed to, and has a history of, a reliable supply chain.16
NHS list price of 120 dose presentations of extrafine beclometasone and formoterol in 100/6mcg and 200/6mcg strengths
| Hello | Pack strength | Fostair | Luforbec | Bibecfo |
|---|---|---|---|---|
| Producto 1 | 100/6mcg | £29.32 | £20.52 | £13.98 |
| Producto 2 | 200/6mcg | £29.32 | £20.52 | £13.98 |
Costs documented September 2023 from the Dictionary of Medicines and Devices (dm+d)3
Fostair is a registered trademark of Chiesi Ltd
Luforbec is a registered trademark of Lupin Ltd.
Bibecfo indications
Bibecfo 100/6mcg and 200/6mcg are indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting β₂-agonist) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting β₂-agonist
or
- patients already adequately controlled on both inhaled corticosteroids and long-acting β₂-agonists.1,2
Bibecfo 100/6mcg is indicated in the symptomatic treatment of patients with severe COPD (FEV1 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.1
Bibecfo 100/6mcg and 200/6mcg are indicated in adults 18 years and above. For Bibecfo 100/6mcg in asthma, no recommendation on a dose can be made in children and adolescents 17 years and under.
